Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > March 21, 2024
Daily News
March 21, 2024
- Will Kyowa Kirin’s Eye Drops for nAMD Replace Intraocular Injections? PII Now Underway
March 21, 2024
- Meiji’s Bivalent COVID Jab Hits Primary Goal in PIII Omicron Trial; New Strains Eyed
March 21, 2024
- New LDP Project Team Launched to Boost Global Access to Infectious Disease Drugs
March 21, 2024
- Arexvy Already January GP Rep Promotion Champion, Tarlige Tops HP Ranking
March 21, 2024
- SanBio Chief Baffled by Planned Advisory Session over Lead Cell Therapy
March 21, 2024
- Shipments Restricted or Halted for 26.6% of Drugs in February: FPMAJ
March 21, 2024
- JCR Hits 1st Milestone in Alexion Collab for Neurodegenerative Disease
March 21, 2024
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s FY2026 drug pricing reform is set to usher in a new phase for the generics market, effectively bringing an…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…